lbt-999
Small moleculeexperimentalImaging agent
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 14, 2025 (NCT06930261)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Dopamine transporterINHIBITOR
SLC6A3 inhibitor
Chemistry & pharmacology
- Imaging
- 18-flourine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06930261 | Phase 2 | Jan 14, 2025 | Institut National de la Santé Et de la Recherche Médicale, France |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Institut National de la Santé Et de la Recherche Médicale, France | Academic/Hospital | 1 | 1 | 1 | 2025 |
1 organizations
Page 1 / 1